RHBC Clinical Trial
A 12-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Comparing the Efficacy and Safety of LY2439821 to Etanercept and Placebo in Patients with Moderate to Severe Plaque Psoriasis with a Long-Term Extension Period
Status: Open to Enrollment
End Date: OPEN
Dr. Kristina Callis Duffin at the University Of Utah Department Of Dermatology is enrolling participants for the Double Blind, and Placebo-Controlled study of LY2439821 (also called ixekizumab) in patients with moderate to severe plaque psoriasis. Ixekizumab is being developed by Eli Lilly (the “Sponsor”), a pharmaceutical company based in the United States.
The following are definitions pertaining to this study:
Randomized Trial: A research trial usually involves comparing different treatments. In a trial, one group will get one treatment and another group will get a different treatment. In a “randomized trial” people are put in one group or the other by random chance. This means that a computer will decide by chance which group a person is in, not the doctors running the trial.
Double Blind Trial: In this trial, neither you nor your doctor will know which treatment group you are in (although, if your doctor needs to find out for important medical reasons, he/she can do so) e.g. if you require emergency treatment.
Because we are testing the efficacy of ixekizumab we need to compare it to a placebo.
A placebo: is a dummy treatment which looks like the study drug but it is not. Placebos contain no drugs or active ingredients. Study participants are given placebos so that the effects of a drug can be compared against no drug. Use of placebos also prevents the participant and the doctor from knowing whether or not the subject is getting the drug.
This is a 12 week study that will study the effectiveness of Ixekizumab to Etanercept and Placebo in patients with moderate to severe plaque psoriasis. You will be assigned to receive treatment with ixekizumab, etanercept, and/or placebo for the first 12 weeks of the study. The probability that you will receive ixekizumab is 4 in 7 or 57%. At 12 weeks you will be reassigned to ixekizumab every 4 weeks for the rest of your time in the study (up to 5 years), depending on your response to treatment.
This study will determine:
- How ixekizumab compares to placebo as treatment for your psoriasis.
- How ixekizumab compares to etanercept as treatment for your psoriasis.
- 18-75 years of age
- Diagnosed moderate to severe plaque psoriasis for at least 6 months.
*Other criteria must be met in order to participate.Contact Information